Zobrazeno 1 - 10 of 79 pro vyhledávání: '"Ping-Hsun Chen"'
1
Akademický článek
以不正方法取得營業秘密之未遂犯 ──美國法著手犯的借鏡 Criminal Attempt of Improperly Acquiring Trade Secrets Under the Trade Secret Act ―A Lesson from the Concept of 'Attempt' Under the United States Criminal Law
Autor: 陳秉訓 Ping-Hsun Chen
Publikováno v: 交大法學評論, Iss 13, Pp 89-121 (2023)
本文意在參酌美國聯邦《經濟間諜法》（Economic Espionage Act, EEA）與《模範刑法法典》（Model Penal Code, MPC）第5.01條之著手犯之法制，來思考我國營業秘密法犯罪行為中的未遂犯意涵。本文指出
Externí odkaz: https://doaj.org/article/89e751cb1ea441758ccdf519672b6361
Zobrazit plný text záznamu
2
Akademický článek
論涉及專利連結之專利侵權訴訟 與其訴訟標的價額之計算 Patent-Linkage-Related Patent Infringement Civil Litigation and Valuation of a Cause of Action
Autor: 陳秉訓 Ping-Hsun Chen
Publikováno v: 交大法學評論, Iss 10, Pp 49-97 (2022)
2019 年起藥事法實施專利連結制度，於學名藥廠申請學名藥藥品許可證之過程中，提供原藥廠提早解決專利權侵害爭議之機制。本文意在藉由過去智財法院涉及藥品專利的民事訴訟裁定，共
Externí odkaz: https://doaj.org/article/7295dc7be61e492ebe6f2faac898f3e5
Zobrazit plný text záznamu
6
Akademický článek
論美國專利訴訟之專家證人資格―以美國聯邦巡迴上訴法院與聯邦證據規則第702條有關之判決為中心 Qualification of Expert Witnesses in United States Patent Litigation: A Review of Federal Circuit Case Law Regarding Rule 702 of the Federal
Autor: 陳秉訓 Ping-Hsun Chen
Publikováno v: Kējì Fǎxué Pínglùn, Vol 11, Iss 1, Pp 155-220 (2014)
專家證人在美國專利訴訟中扮演重要的角色。專利訴訟常涉及技術議題，需要技術專家的參與來幫助解釋請求項或協助陪審團瞭解專利技術或侵權物。當處理可專利性爭點時，技術專家則是
Externí odkaz: https://doaj.org/article/5c667426679449fa8dea0dcec8c73b96
Zobrazit plný text záznamu
7
Taiwan's Efforts to Recreate Remdesivir
Autor: Ping-Hsun Chen
Publikováno v: Biotechnology Law Report. 40:174-183
This article reports Taiwan's efforts to replicate remdesivir to prepare for combating COVID-19. There were two state-funded institutions and two private pharmaceutical companies working on remdesi...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::89202273e4f59e703c9c7dc6b0692dd0
https://doi.org/10.1089/blr.2021.29227.phc
Zobrazit plný text záznamu
8
Incorrect Translation Causing a Claim to Be Indefinite Under 35 U.S.C. § 112—A Case Study of IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc
Autor: Ping-Hsun Chen
Publikováno v: Biotechnology Law Report. 39:452-457
IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc., 966 F.3d 1374 (Fed. Cir. 2020), shows a case of inaccurate translation leading the court to find the asserted claims invalid. The ...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::faca319ea294152ad8ac605126fcba92
https://doi.org/10.1089/blr.2020.29208.phc
Zobrazit plný text záznamu
9
A Design-Around Solution for a MMX-Based Tablet Drug Comprising Mesalazine—A Lesson from Shire Development, LLC v. Watson Pharmaceuticals, Inc
Autor: Ping-Hsun Chen
Publikováno v: Biotechnology Law Report. 39:25-32
This article explores Shire Development, LLC v. Watson Pharmaceuticals, Inc., 848 F.3d 981 (Fed. Cir. 2017) and illustrates some implications for designing around a MMX-based tablet drug, Lialda. T...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::728df82483fd4ac2fd806de978126133
https://doi.org/10.1089/blr.2019.29155.pc
Zobrazit plný text záznamu
10
Trade Secret Protection of Genetically Engineered Rice Through the Economic Espionage Act: A Lesson from United States v. Weiqiang Zhang
Autor: Ping-Hsun Chen
Publikováno v: Biotechnology Law Report. 37:205-210
Kansas-based Ventria Bioscience Inc. developed genetically engineered rice seeds that would be used in the therapeutic and medical fields. Unfortunately, one of Ventria's employees worked ...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ed24b50cbd6d4160c3c80adb15b81da2
https://doi.org/10.1089/blr.2018.29075.sz
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje